Pregled bibliografske jedinice broj: 327378
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment // International Journal of Pancreatology, 29 (2001), 1; 19-23 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 327378 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment
Autori
Phan, T. P. ; Crane, C. H. ; Janjan, N. A. ; Vrdoljak, Eduard ; Milas, L. ; Mason, K. A.
Izvornik
International Journal of Pancreatology (0169-4197) 29
(2001), 1;
19-23
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
gemcitabine; WR-2721; radiation demage; radioprotector; pancreatic cancer
Sažetak
Background: The nucleoside analog gemcitabine is a potent radiosensitizer of both tumor and normal mucosa, so severe toxic reactions have resulted from its combination with radiation in some clinical treatment schedules for pancreatic cancer. WR-2721 (amifostine) has been shown to reduce normal tissue toxicity produced from both radiation treatment and some chemotherapeutics. The aim of this study was to determine if WR-2721 can protect the gastrointestinal mucosa from injury by concurrent gemcitabine and radiation treatment. Methods and Materials: Gemcitabine was injected ip into C3Hf/Kam mice at a concentration of 33 mg/kg 24 h before whole-body irradiation. A single dose (200 mg/kg) of WR-2721 was given 30 min before the radiation treatment or 30 min before gemcitabine or at both times. A quantitative assessment of the chemotherapy/radiation-induced damage was carried out using the mouse microcolony assay for stem cell survival in the intestinal crypts. RESULTS: WR-2721 given 30 min before gemcitabine followed 24 h later by radiation did not confer any protection to the jejunum (DMF 0.95). However, WR-2721 administered 30 min before radiation without or with prior gemcitabine produced protection factors (PF) of 1.35 and 1.42 Conclusions: WR-2721 did not directly protect the gastrointestinal mucosa from gemcitabine toxicity, but it did protect the gemcitabine-radiosensitized mucosa from acute radiation damage by a factor of 1.42. Therefore, in clinical treatment protocols using concurrent chemoradiation with gemcitabine, WR-2721 may have clinical utility in protecting against radiation-induced mucosal toxicity.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE